Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1204 - Multiobjective optimization reveals distinct cancer-testis antigen patterns by primary site and Human Papilloma Virus status in head and neck squamous cell carcinoma

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Simon Laban

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

S. Laban1, G. Völkel2, J. Ezic1, T.K. Hoffmann1, H. Rammensee3, J. Döscher1, P.J. Schuler1, C. Brunner1, J. Kraus2, H. Kestler2

Author affiliations

  • 1 Department Of Otorhinolaryngology And Head & Neck Surgery, University Medical Center Ulm, 89075 Ulm - Ulm/DE
  • 2 Institute For Medical Systems Biology, Ulm University, 89070 - Ulm/DE
  • 3 Department Of Immunology, University of Tübingen, 72076 - Tübingen/DE

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1204

Background

Most previous vaccination attempts in cancer immunotherapy have been focused on a single antigen. Consequently, the expression of the selected antigen needs to be determined before trial inclusion resulting in a high screening failure rate. The establishment of a multi-antigen vaccine may improve the coverage of potential patients, especially if the selected antigens are semipersonalized for clinical patient subgroups.

Methods

Analysis and Visualization of Alteration Data (AVATAR), a novel bioinformatic software tool for multi-objective optimization of large datasets, was used to analyze publicly available datasets of transcriptome data from The Cancer Genome Atlas (TCGA) and a dataset from Gene Expression Omnibus (GSE 40774). Cancer-testis antigens (CTA) were selected as model antigens for multi-objective optimization based on the primary tumor site and HPV-status. Dichotomized data were pooled and edited resulting in a cohort of 865 patients, of which 125 were HPV-positive (HPV+). Primary tumor sites included were oral cavity (n = 208), oropharynx (n = 150) and larynx (n = 208).

Results

Selecting 10 CTA genes for the whole cohort results in a coverage of 89.3%. When optimizing gene selections for each primary tumor site, distinct 10-gene-selections are revealed improving the coverage in the respective group markedly. Antigen selections overlap only to a minor degree with the solutions for all patients or other patient groups. Even in predominantly HPV- primary sites such as OC and L, antigen selections are remarkably different from each other. When optimizing for HPV-status, distinct selections were found for optimal coverage in the respective patient group overlapping only in one gene.

Conclusions

AVATAR can be used to identify antigen selections with optimal coverage within a specified patient group. A semi-personalized antigen selection based on multi-objective optimization may be a useful strategy to plan trials for antigen-specific vaccination.

Clinical trial identification

Legal entity responsible for the study

University Medical Center Ulm.

Funding

Deutsche Forschungsgemeinschaft (GRK2254).

Editorial Acknowledgement

Disclosure

S. Laban: Advisory board member: AstraZeneca, Merck Sharp & Dohme; Lecture fees: Bristol-Myers Squibb, Merck Serono. G. Völkel, H. Kestler, J. Kraus: Developers of Analysis and Visualization of Alteration Data (AVATAR) software. T.K. Hoffmann: Advisory board member: MSD, Merck Serono. H.-G. Rammensee: Cofounder and shareholder: Immatics, CureVac, Synimmune. P.J. Schuler: Advisory board member: Bristol-Myers Squibb. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.